What is the price-to-earnings ratio of Immunic?
The price-earnings ratio of Immunic is currently -0.64.
Immunic P/E 2024
Immunic P/E
-0.64
Ticker
IMUX
ISIN
US4525EP1011
WKN
A2PHD4
As of Nov 8, 2024, Immunic's P/E ratio was -0.64, a -16.88% change from the -0.77 P/E ratio recorded in the previous year.
The Immunic P/E history
Immunic Aktienanalyse
What does Immunic do?
Immunic Inc is a biotechnology company specialized in the development of therapeutics for chronic inflammatory and autoimmune diseases. The company was founded in 2016 as a spin-off of the Max Planck Institute for Infection Biology in Berlin and is based in New York City. Immunic Inc aims to develop innovative drugs that improve the quality of life for patients with chronic inflammatory and autoimmune diseases and positively influence the course of their conditions. The business activities of Immunic Inc include the identification of new active substances, drug development, clinical studies, and drug approval by regulatory authorities. To accelerate drug development, the company collaborates with academic, regulatory, and pharmaceutical partners. Immunic Inc offers products in three different areas: autoimmune diseases, inflammatory diseases, and infectious diseases. Each area has various products and pipelines currently in development. In the field of autoimmune diseases, the main product of Immunic Inc is the substance IMU-838. This drug is a highly effective inhibitor of the DHODH enzyme family, which plays an essential role in mitochondrial DNA synthesis. IMU-838 is a very selective DHODH inhibitor with disease-specific effects against various autoimmune diseases. IMU-838 is one of the most promising candidates of Immunic Inc and is currently in phase II studies for the treatment of multiple sclerosis (MS), ulcerative colitis, and chronic inflammatory bowel diseases (CED). In the field of inflammatory diseases, Immunic Inc is developing a drug based on IMM-124E. This medication is an orally administered therapeutic agent that inhibits inflammatory reactions in the gastrointestinal tract. IMM-124E was initially developed as an antidote for arsenic poisoning but also shows promising results in the treatment of inflammatory diseases such as nonalcoholic steatohepatitis (NASH) and liver fibrosis. IMM-124E is currently in phase II studies for the treatment of these conditions. In the field of infectious diseases, Immunic Inc is developing various drugs that are effective against infections. This includes IMU-935, a selective HSV-1 inhibitor that has shown promise in the treatment of herpes simplex viruses (HSV) and other viral infections. IMU-935 also exhibits good activity against influenza viruses and cytomegaloviruses and is currently in phase I studies. Immunic Inc is an innovative biotechnology company developing innovative therapeutics for chronic inflammatory and autoimmune diseases. The company aims to improve the lives of patients with chronic conditions and positively influence the course of their diseases. By focusing on three different areas, the company is developing a broad portfolio of drugs in various stages of development and clinical testing. Immunic Inc has established strong partnerships with academic, regulatory, and pharmaceutical partners and will continue to operate successfully in the biotechnology field with promising products and pipelines in the coming years. Immunic ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/E Details
Deciphering Immunic's P/E Ratio
The Price to Earnings (P/E) Ratio of Immunic is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.
Year-to-Year Comparison
Assessing Immunic's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.
Impact on Investments
The P/E ratio of Immunic is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.
Interpreting P/E Ratio Fluctuations
Fluctuations in Immunic’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.
Frequently Asked Questions about Immunic stock
How has the price-earnings ratio of Immunic changed compared to last year?
The price-to-earnings ratio of Immunic has increased by -16.88% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Immunic high compared to other companies?
Yes, the price-to-earnings ratio of Immunic is high compared to other companies.
How does an increase in the price-earnings ratio of Immunic affect the company?
An increase in the price-earnings ratio of Immunic would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Immunic affect the company?
A decrease in the price-earnings ratio of Immunic would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Immunic?
Some factors that influence the price-earnings ratio of Immunic are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Immunic pay?
Over the past 12 months, Immunic paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immunic is expected to pay a dividend of 0 USD.
What is the dividend yield of Immunic?
The current dividend yield of Immunic is .
When does Immunic pay dividends?
Immunic pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Immunic?
Immunic paid dividends every year for the past 0 years.
What is the dividend of Immunic?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Immunic located?
Immunic is assigned to the 'Health' sector.
Wann musste ich die Aktien von Immunic kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Immunic from 11/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/8/2024.
When did Immunic pay the last dividend?
The last dividend was paid out on 11/8/2024.
What was the dividend of Immunic in the year 2023?
In the year 2023, Immunic distributed 0 USD as dividends.
In which currency does Immunic pay out the dividend?
The dividends of Immunic are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Immunic
Our stock analysis for Immunic Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunic Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
